Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Dana DiRenzo, MD, RhMSUS, MHS
University of Pennsylvania
Philadelphia, PA, United States
Disclosure information not submitted.
Kaleb Michaud, PhD (he/him/his)
University of Nebraska Medical Center
Omaha, Nebraska, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
This session will review the science of medical cannabis and its applications to patient care, including a review of the endocannabinoid system and the pathophysiologic effects of cannabis as an analgesic and immune-modulatory drug, with a particular focus on its role in rheumatic diseases. Regulatory issues and long-term safety data of medical cannabis will be discussed, along with the limitations in the data so that patients can be counseled appropriately. Understanding medical cannabis from the patient perspective and how to appropriately discuss this topic with patients will be emphasized.
Speaker: Daniel Clauw, MD – University of Michigan
Speaker: Bharat Kumar, MD;RhMSUS;MMed – University of Iowa Hospitals and Clinics